. Author manuscript; available in PMC: 2024 Jun 3.

Published in final edited form as: Value Health. 2023 Feb 18;26(8):1155–1163. doi: 10.1016/j.jval.2023.02.007

Table 3.

US EQ-5D-5L and EORTC QLU-C10D utility linear mixed model estimated coefficients for TTD-based Models 3a and 3b

	EQ-5D-5L		EORTC QLU-C10D
	Model 3a^*	Model 3b^†	Model 3a^*	Model 3b^†
Intercept^‡ (SE)	0.5926 (0.0250)	0.5848 (0.0286)	0.6472 (0.0189)	0.6433 (0.0216)
≥28 to <182 days to death (SE)	0.1045 (0.0228)	0.1045 (0.0228)	0.0533 (0.0172)	0.0533 (0.0172)
≥182 to <364 days to death (SE)	0.1364 (0.0235)	0.1362 (0.0235)	0.0910 (0.0177)	0.0909 (0.0177)
≥364 days to death (SE)	0.1484 (0.0246)	0.1482 (0.0246)	0.0859 (0.0186)	0.0858 (0.0186)
Previously treated (SE)	–	0.0156 (0.0276)	–	0.0077 (0.0208)

Coefficients for significant covariates are shown in bold.

Includes a random intercept and fixed effects for TTD categories.

^†

Includes a random intercept and fixed effects for TTD categories and prior treatment status.

^‡

Corresponds to utilities at <28 days to death overall (Model 3a) or utilities at <28 days to death in treatment-naïve patients (Model 3b).

EORTC, European Organisation for Research and Treatment of Cancer; QLU-C10D, Quality of Life Utility Measure Core 10 Dimensions; SE, standard error; TTD, time-to-death.